WO2006077494A2 - Procede de preparation de formes dosifiees solides pour la liberation prolongee de biguanide et de sulfonyluree - Google Patents

Procede de preparation de formes dosifiees solides pour la liberation prolongee de biguanide et de sulfonyluree Download PDF

Info

Publication number
WO2006077494A2
WO2006077494A2 PCT/IB2006/000102 IB2006000102W WO2006077494A2 WO 2006077494 A2 WO2006077494 A2 WO 2006077494A2 IB 2006000102 W IB2006000102 W IB 2006000102W WO 2006077494 A2 WO2006077494 A2 WO 2006077494A2
Authority
WO
WIPO (PCT)
Prior art keywords
extended
release
layered tablet
layer
tablet
Prior art date
Application number
PCT/IB2006/000102
Other languages
English (en)
Other versions
WO2006077494A3 (fr
Inventor
Amit Kumar Kesarwani
Manish Chawla
Rajeev Singh Raghuvanishi
Ashok Rampal
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2006077494A2 publication Critical patent/WO2006077494A2/fr
Publication of WO2006077494A3 publication Critical patent/WO2006077494A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Definitions

  • the present invention relates to solid extended-release dosage forms comprising biguanide and sulfonylurea.
  • the invention relates to layered extended-release tablets combining highly water-soluble, high dose metformin and water-insoluble, low-dose glipizide.
  • antidiabetic drugs People suffering from Type 2 diabetes may eventually require more than one category of antidiabetic medication. Studies show that when needed, combining 2 or more antidiabetic drugs with different mechanisms of action can be very effective due to complementary and additive effects of such combinations.
  • a combination therapy of a biguanide and a sulfonylurea has a synergistic effect on glucose control since both agents act by different but complementary mechanisms.
  • Such combination therapies can facilitate effective metabolic control in Non Insulin Dependent Diabetes Mellitus (NIDDM) patients where monotherapy using only sulfonylurea or only biguanide becomes ineffective over the course of treatment.
  • NIDDM Non Insulin Dependent Diabetes Mellitus
  • Other advantages of fixed dose combinations include, for example, providing simple regimen due to lesser dosage, resulting in improved patient compliance and convenience; and reducing overall cost of therapy by combining two or more drugs in one dosage form when compared to individual administration of dosage forms.
  • compositions having combinations of biguanides and sulfonylureas providing for controlled or immediate release of both the drugs have been disclosed.
  • Bristol Myers Squibb is currently marketing a combination of glipizide and metformin HCl tablets under the brand name MetaglipTM.
  • MetaglipTM was shown to be more effective in lowering blood sugar levels than either glipizide or metformin when used alone in patients with type 2 diabetes.
  • metformin and a sulfonylurea, including glipizide is known.
  • Both metformin hydrochloride and glipizide are commercially available individually as extended-release dosage forms.
  • Extended-release glipizide formulations are commercially available as osmotic dosage forms (Glucotrol XLTM), which are complex and costlier to prepare. These also exhibit another disadvantage of an initial lag in the release of glipizide.
  • extended-release metformin formulations are currently marketed as biphasic dosage forms (Glucophage XRTM). However, no such formulation is available that contains extended-release metformin in combination with an extended-release glipizide in one single dosage form so as to achieve a once-daily administration for both the drugs.
  • Formulating a metformin/glipizide extended-release combination in a single dosage form poses many challenges.
  • Metformin is commercially available as a tablet in the dose range of 500-1000 mg.
  • Glipizide is available as 2.5, 5.0 and 10 mg tablets.
  • glipizide is used in a micronized form due to its poor solubility, whereas metformin is freely soluble.
  • content uniformity of glipizide poses significant problems.
  • the different solubilities of glipizide and metformin make selecting suitable rate-controlling polymers difficult.
  • WO 2005/107717 discloses various ways of combining a biguanide and a sulfonylurea, i.e., monolithic matrix dosage forms, bi- or multi- layered tablets, multiparticulates, etc.
  • layered tablets comprising a layer containing a first portion of biguanide and a second layer containing sulfonylurea and a second portion of biguanide.
  • the layered tablets provide rapid onset of action for biguanide as the presence of biguanide in both the layers results in simultaneous release of the highly water-soluble drug form the two layers.
  • Layered tablets described herein can completely and rapidly release sulfonylurea.
  • Preferred biguanides include metformin and preferred sulfonylurea sulfonylureas include glipizide.
  • Glipizide is highly hydrophobic in nature, facilitating delayed release from a polymeric matrix.
  • glipizide When metformin is also present, glipizide is rapidly and completely released due to the highly hydrophilic nature of glipizide. Further, the total amount of polymer(s) required to achieve the desired drug release rate is reduced because high dosage amounts of metformin is present in both the layers. As a result, tablet sizes can be decreased. Another advantage of these bilayered tablets is the reduction in layer separation problem commonly observed with bilayered tablets, particularly when similar types of polymers are incorporated in both the layers, which increases adhesion between these layers.
  • extended-release layered tablets comprising: a first layer comprising one or more biguanides, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients, and a second layer comprising one or more sulfonylureas, one or more biguanides, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients.
  • Such extended-release layered tablets can include one or more of the following embodiments.
  • the one or more biguanides can be metformin and the one or more sulfonylureas can be glipizide, glimeperide or a mixture thereof.
  • Metformin can be present from about 20 % to about 80% by weight of the extended-release layered tablet.
  • Glipizide can be present in about 0.05 % to about 10% by weight of the extended- release layered tablet.
  • Glimepiride can be present in about 0.05 % to about 10% by weight of the extended-release layered tablet.
  • the one or more rate-controlling polymers can be hydrophilic polymers, hydrophobic polymers or a combination thereof.
  • the hydrophilic polymers can be selected from cellulose derivatives; polyvinylpyrrolidone, vinyl acetate/vinyl pyrrolidone copolymer, microcrystalline cellulose, polysaccharides, polyalkylene glycols, starch or derivatives thereof, or mixtures thereof.
  • the cellulose derivatives can be selected from hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxy ethylcellulose, hydroxymethylcellulose, carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose or mixtures thereof.
  • the hydrophobic polymers can be selected from ethyl cellulose, cellulose acetate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, poly(alkyl)methacrylate, copolymers of acrylic or methacrylic acid esters, waxes, shellac, hydrogenated vegetable oils or mixtures thereof.
  • the one or more rate-controlling polymers can be present in about 5 % to about 60 % w/w of the extended-release layered tablet.
  • the first and second layers are prepared by dry granulation, wet granulation, direct compression or a combination thereof.
  • the one or more pharmaceutically acceptable excipients are selected from diluents, binders, lubricants, glidants, colorants, flavoring agents or mixtures thereof.
  • the second layer further comprises one or more alkalizing agents.
  • the extended-release layered tablets can further comprise one or more outer protective coating layers, one or more separating layers between the first layer and the second layer, or a combinations thereof.
  • the extended-release layered tablets can provides an in-vitro release of glipizide of from about 8 % to about 15 % by weight after one hour, from about 15 % to about 30 % by weight after 2 hours and from about 20 % to about 50 % by weight after 4 hours, when measured by the USP Paddle Method at 50 rpm in 900 mL of simulated intestinal fluid at 37 0 C.
  • Also provided are processes for preparing layered tablets comprising the steps of: a. preparing a first mixture comprising one or more biguanides, one or more rate- controlling polymers and one or more pharmaceutically acceptable excipients, b. preparing a second mixture comprising one or more sulfonylureas, one or more biguanides, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients, and c. forming a first layer and a second layer and combining the layers in a single tablet to form a layered tablet.
  • Also provided are methods for treating non-insulin dependent diabetes mellitus comprising administering to a patient in need thereof an extended-release layered tablet comprising: a first layer comprising one or more biguanides, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients, and a second layer comprising one or more sulfonylureas, one or more biguanides, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients.
  • layered tablets comprising: a layer comprising one or more biguanides, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients; and a second layer comprising one or more sulfonylureas, one or more biguanides, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients.
  • Such tablets provide extended-release of biguanide and sulfonylurea.
  • Another aspect provides layered tablets comprising: a layer comprising metformin, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients, and a second layer comprising glipizide, metformin, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients.
  • Such tablets provide extended-release of metformin and glipizide.
  • Another aspect provides layered tablets comprising: a layer comprising metformin, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients, and a second layer comprising glimepiride, metformin, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients.
  • Such tablets provide extended-release of metformin and glimepiride.
  • the rate-controlling polymers used in each layer are similar, particularly in chemical structure, chemical properties and/or physical properties. Using similar rate-controlling polymers improves adhesion between the two layers and reduces the possibility of separation of layers, for example, on storage, as well as after coming in contact with gastric fluids.
  • Another aspect provides layered tablets comprising sulfonylurea and high dosage amounts of one or more biguanides and such tablets are of size sufficient for convenient oral administration.
  • Another aspect provides layered tablets comprising metformin and glipizide, which exhibit an in-vitro release of glipizide of from about 8 % to about 15 % by weight after one hour, from about 15 % to about 30 % by weight after 2 hours and from about 20 % to about 50 % by weight after 4 hours, when measured by the USP Paddle Method at 50 rpm in 900 mL of simulated intestinal fluid at 37 °C.
  • Another aspect provides processes for preparing a layered tablet comprising the steps of: a.
  • first mixture comprising one or more biguanides, one or more rate- controlling polymers and one or more pharmaceutically acceptable excipients
  • second mixture comprising one or more sulfonylureas, one or more biguanides, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients
  • c. forming a first layer and a second layer and combining the layers in a single tablet to form a layered tablet.
  • the first layer can be formed by compressing the first mixture and the second layer can be formed by compressing the second mixture.
  • the first mixture can be granulated to form granules prior to compression to form the first layer.
  • the second mixture can be granulated to form granules comprising one or more sulfonylureas, one or more biguanides, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients.
  • granules When granules are used, they may be formed by wet granulation or dry granulation.
  • Another aspect provides methods for treating non-insulin dependent diabetes mellitus comprising administering to a patient in need thereof a layered extended-release tablet comprising: a first layer comprising one or more biguanides, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients, and a second layer comprising one or more sulfonylureas, one or more biguanides, one or more rate-controlling polymers and one or more pharmaceutically acceptable excipients.
  • Such extended-release tablets provide extended-release of biguanide and sulfonylurea.
  • Layered tablets described herein may further include one or more of glitazones, insulin, alpha-glucosidase inhibitors, meglitinides, fibrates, statins, squalene synthesis inhibitors, angiotensin-converting enzyme inhibitors or mixtures thereof.
  • layered tablets described herein may also comprise one or more additional non-drug containing layers, for example, separating layers or coating layers.
  • Biguanides as used herein includes metformin, phenformin and buformin, as well as their salts, solvates, hydrates and polymorphs thereof.
  • a particularly preferred biguanide is metformin.
  • Metformin as used herein includes the base per se or a pharmaceutically acceptable salt thereof.
  • the pharmaceutically acceptable salt may be a hydrochloride, fumarate, hydrobromide, succinate or embonate salt.
  • Daily effective doses of biguanides, for example, metformin may range from about 500 mg to 2550 mg, and in particular, the dose is a single dose of about 250 mg to 1000 mg.
  • Biguanides can be present in amounts from about 20 % to about 80 % by weight of the tablet, from about 25 % to about 75 % by weight of the tablet, and even from about 27.5 % to about 55 % by weight of the tablet.
  • Sulfonylurea as used herein is intended to include, but not limited to, glipizide, glimepiride, glibornuride, glyburide, glisoxepide, gliclazide, acetohexamide, chlorpropamide, tolazamide, tolbutamide, and the like, as well as other medicinally active and pharmaceutically acceptable forms from the sulfonylurea class of compounds, including their salts, solvates, hydrates, polymorphs, complexes or such other products.
  • a particularly preferred sulfonylurea is glipizide.
  • the daily effective dose of sulfonylureas may range from about 2.5 mg to 20 mg, and in particular, the dose is a single dose of about 2.5 mg to 10 mg,.
  • Sulfonylureas for example glipizide, can be present in an amount from about 0.05 % to about 10 % by weight of the tablet and even from about 0.1 % to about 5 % by weight of the tablet.
  • Rate-controlling polymers may be hydrophilic, hydrophobic or a combination thereof. Rate-controlling polymers can comprise from about 5 % to 60 % w/w of the tablet.
  • Suitable hydrophilic polymers include one or more of cellulose derivatives (for example, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose or mixtures thereof); polyvinyl pyrrolidone; vinyl acetate/vinyl pyrrolidone copolymer; microcrystalline cellulose; polysaccharides; polyalkylene glycols; starch and derivatives thereof; or mixtures thereof.
  • cellulose derivatives for example, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose or mixtures thereof
  • polyvinyl pyrrolidone vinyl acetate/vinyl pyrrolidone copolymer
  • microcrystalline cellulose polysaccharides
  • polyalkylene glycols starch and derivatives thereof; or mixtures thereof.
  • Suitable hydrophobic polymers include one or more of ethyl cellulose, cellulose acetate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, poly(alkyl) methacrylate, and copolymers of acrylic or methacrylic acid esters, waxes, shellac, hydrogenated vegetable oils or mixtures thereof.
  • Tablet layers may be prepared by any pharmaceutically acceptable technique that achieves uniform blending, e.g. dry granulation, wet granulation or direct compression.
  • Tablet layers may contain other pharmaceutically acceptable excipients, which act in one or more capacities as diluents, binders, lubricants, glidants, colorants or flavoring agents.
  • Suitable diluents include, for example, pharmaceutically acceptable inert fillers, for example, microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol, starch, sorbitol, sucrose, dextrose, maltodextrin or mixtures thereof.
  • Suitable binders include, for example, polyvinyl pyrrolidone, vinyl acetate/vinyl pyrrolidone copolymer, microcrystalline cellulose, lactose, starches, gums, waxes, gelatin, polymers or mixtures thereof.
  • Suitable lubricants include, for example, colloidal silicon dioxide, talc, stearic acid, magnesium stearate, magnesium silicate, sodium benzoate, polyethylene glycol, sodium lauryl sulphate, fumaric acid, zinc stearate, paraffin, glyceryl behenate or mixtures thereof.
  • Suitable glidants include, for example, talc, colloidal silicon dioxide or mixtures thereof.
  • alkalizing agents may be included in the layer comprising glipizide to facilitate optimal dissolution and release of active agents from the layer. Such alkalizing agents also ensure substantially complete bioavailability of glipizide. Suitable alkalizing excipients include sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, magnesium oxide, ammonia, tertiary sodium phosphate, basic amino acids (for example, diethanolamine, ethylenediamine, N-methylglucamine, 6 N-methyl-glucamine or L- lysine and/or mixtures thereof), or mixtures thereof. Alkalizing agents may be added to the layer comprising glipizide extragranularly.
  • Each layer comprising sulfonylurea and/or biguanide may be formed by compressing mixtures thereof separately and the layers combined and compressed together to form a layered tablet employing conventional layered tableting techniques and equipment.
  • each layer may be compressed in such a manner that one layer envelopes the second layer on all the sides except the top surface to produce inlay tablets.
  • the first layer can be compressed first and then the enveloping layer can be compressed around it, leaving only the top surface of the first layer exposed.
  • compositions which may optionally be present in any layer, include preservatives, stabilizers, colorants, anti-adherents, antioxidants or mixtures thereof.
  • Layered tablets may also include one or more outer protective coating layer or one or more separating layer between the two drug layers.
  • Protective coating layers or separating layers may include one or more film-formers or binders, for example, hydrophilic polymers (e.g., hydroxypropyl methyl cellulose) hydrophobic polymers (e.g., ethyl cellulose, cellulose acetate, polyvinyl alcohol-maleic anhydride copolymers, acrylic copolymers, glyceryl esters of wood resins or mixtures thereof), enteric polymers (e.g., polyacrylate material, cellulose acetate phthalate, cellulose phthalate hydroxy propyl methyl ether, polyvinyl acetate phthalate, hydroxy propyl methyl cellulose acetate succinate, cellulose acetate trimellitate, shellac or mixtures thereof), or mixtures thereof.
  • hydrophilic polymers e.g., hydroxypropyl methyl cellulose
  • hydrophobic polymers
  • the protective coating layers can also include other pharmaceutically acceptable excipients, such as plasticizers, lubricants, colors or mixtures thereof.
  • plasticizers include, for example, polyethylene glycol, triethyl citrate, diethyl phthalate, propylene glycol, glycerin, butyl phthalate, castor oil or mixtures thereof.
  • Film formers can be applied from a solvent system containing one or more solvents including, for example, water, one or more alcohols (e.g., methyl alcohol, ethyl alcohol, isopropyl alcohol or mixtures thereof), ketones (e.g., acetone, ethylmethyl ketone or mixtures thereof), chlorinated hydrocarbons (e.g., methylene chloride, dichloroethane, 1,1,1- trichloroethane or mixtures thereof), or mixtures thereof.
  • solvents including, for example, water, one or more alcohols (e.g., methyl alcohol, ethyl alcohol, isopropyl alcohol or mixtures thereof), ketones (e.g., acetone, ethylmethyl ketone or mixtures thereof), chlorinated hydrocarbons (e.g., methylene chloride, dichloroethane, 1,1,1- trichloroethane or mixtures thereof), or mixtures thereof.
  • alcohols e
  • Metformin hydrochloride was blended with hydroxypropyl methylcellulose, and granulated with an aqueous solution of polyvinyl pyrrolidone.
  • Metformin hydrochloride, glipizide and colorant were blended with hydroxypropyl methylcellulose, colorant, and granulated with an aqueous solution of polyvinyl pyrrolidone. 5. The resulting wet mass was dried and milled to size - BSS mesh size 18.
  • Sized granules were blended with magnesium oxide, talc and magnesium stearate. The two layers were compressed over each other to form a layered tablet.
  • Metformin hydrochloride was blended with hydroxypropyl methylcellulose, and granulated with an aqueous solution of polyvinyl pyrrolidone. 8. The resulting wet mass was dried and milled to size - BSS mesh size 18.
  • Metformin hydrochloride, glipizide and colorant were blended with hydroxypropyl methylcellulose and granulated with an aqueous solution of polyvinyl pyrrolidone. 11. The resulting wet mass was dried and milled to size - BSS mesh size 18.
  • Sized granules were blended with magnesium oxide, talc and magnesium stearate. The two layers were compressed over each other to form a layered tablet.
  • Metformin hydrochloride was blended with hydroxypropyl methylcellulose and granulated with an aqueous solution of polyvinyl pyrrolidone. 14. The resulting wet mass was dried and milled to size - BSS mesh size 18.
  • the milled granules were lubricated with magnesium stearate and talc.
  • Layer II The milled granules were lubricated with magnesium stearate and talc.
  • Metformin hydrochloride, glipizide and colorant were blended with hydroxypropyl methylcellulose and granulated with an aqueous solution of polyvinyl pyrrolidone. 17. The resulting wet mass was dried and milled to size - BSS mesh size 18.
  • Sized granules were blended with lactose, magnesium oxide, talc and magnesium stearate. The two layers were compressed over each other to form a layered tablet.
  • Tables 1 and 2 provide the in- vitro release profiles of metformin and glipizide, respectively, from layered tablets prepared by the composition and process of Examples 1-3 in simulated intestinal fluid (phosphate buffer pH 6.8), 900 mL, USP Apparatus 2 at 50 rpm.
  • Table 1 Release pro ⁇ Ie of metformin from layered tablets prepared as per Examples 1- 3 in simulated intestinal fluid (Phosphate buffer pH 6.8), 900 niL, USP 2 at 50 rpm.
  • Table 2 Release profile of glipizide from layered tablets prepared as per Examples 1-3 in simulated intestinal fluid (Phosphate buffer pH 6.8), 900 niL, USP 2 at 50 rpm.
  • a single fixed dose combination of Metformin ER 500 mg and Glipizide ER 5 mg tablet of Example 1 was compared with twice a day administration of single fixed dose combination of Metformin hydrochloride 250 mg and Glipizide 2.5 mg tablets (MetaglipTM tablets; Bristol Myers Squibb) under fed conditions.
  • Test T Metformin ER + Glipizide ER layered tablets (Example 1)
  • Table 3 Summary of pharmacokinetic parameters for metformin
  • Metformin hydrochloride, glimepiride and colorant were blended with hydroxypropyl methylcellulose, lactose, microcrystalline cellulose and granulated with an aqueous solution of polyvinyl pyrrolidone. 2. The wet mass was dried and milled to size — BSS mesh size 18.
  • Sized granules were blended with lactose, magnesium oxide, talc and magnesium stearate.
  • the two layers were compressed over each other to form a layered tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une forme dosifiée solide combinant le biguanide et la sulfonylurée, qui permet une libération prolongée à la fois du biguanide et de la sulfonylurée. Plus particulièrement, l'invention concerne un comprimé multicouches combinant une dose élevée de métformine hautement hydrosoluble et une faible dose de glipizide non hydrosoluble; ce comprimé permettant une libération prolongée à la fois du métformine et du glipizide.
PCT/IB2006/000102 2005-01-24 2006-01-23 Procede de preparation de formes dosifiees solides pour la liberation prolongee de biguanide et de sulfonyluree WO2006077494A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN140/DEL/2005 2005-01-24
IN140DE2005 2005-01-24

Publications (2)

Publication Number Publication Date
WO2006077494A2 true WO2006077494A2 (fr) 2006-07-27
WO2006077494A3 WO2006077494A3 (fr) 2007-02-08

Family

ID=36603574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/000102 WO2006077494A2 (fr) 2005-01-24 2006-01-23 Procede de preparation de formes dosifiees solides pour la liberation prolongee de biguanide et de sulfonyluree

Country Status (1)

Country Link
WO (1) WO2006077494A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092711A2 (fr) * 2005-03-02 2006-09-08 Ranbaxy Laboratories Limited Comprimes a liberation lente a base de metformine et de glipizide
CN113616613A (zh) * 2021-08-30 2021-11-09 河南合智医药科技有限公司 一种治疗糖尿病用药二甲双胍格列吡嗪复方片剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038650A1 (fr) * 1998-12-23 2000-07-06 Alza Corporation Forme posologique a retention gastrique possedant des couches multiples
WO2003051293A2 (fr) * 2001-12-17 2003-06-26 Bristol-Myers Squibb Company Formulation anti-diabete et procede
WO2005107717A2 (fr) * 2004-05-11 2005-11-17 Ranbaxy Laboratories Limited Forme pharmaceutique orale pour la liberation prolongee d'un biguanide et d'une sulfonyluree
WO2006092711A2 (fr) * 2005-03-02 2006-09-08 Ranbaxy Laboratories Limited Comprimes a liberation lente a base de metformine et de glipizide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038650A1 (fr) * 1998-12-23 2000-07-06 Alza Corporation Forme posologique a retention gastrique possedant des couches multiples
WO2003051293A2 (fr) * 2001-12-17 2003-06-26 Bristol-Myers Squibb Company Formulation anti-diabete et procede
WO2005107717A2 (fr) * 2004-05-11 2005-11-17 Ranbaxy Laboratories Limited Forme pharmaceutique orale pour la liberation prolongee d'un biguanide et d'une sulfonyluree
WO2006092711A2 (fr) * 2005-03-02 2006-09-08 Ranbaxy Laboratories Limited Comprimes a liberation lente a base de metformine et de glipizide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHARPENTIER G ET AL: "IMPROVED GLYCAEMIC CONTROL BY ADDITION OF GLIMEPIRIDE TO METFORMIN MONOTHERAPY IN TYPE 2 DIABETIC PATIENTS" DIABETIC MEDICINE, JOHN WILEY & SONS, LTD, GB, vol. 18, no. 10, 2001, pages 828-834, XP008055309 ISSN: 0742-3071 *
DAVIS S N: "The role of glimepiride in the effective management of Type 2 diabetes" JOURNAL OF DIABETES AND ITS COMPLICATIONS, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 18, no. 6, November 2004 (2004-11), pages 367-376, XP004628198 ISSN: 1056-8727 *
GOLDSTEIN BARRY J ET AL: "Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea." CLINICAL THERAPEUTICS, vol. 25, no. 3, March 2003 (2003-03), pages 890-903, XP002404283 ISSN: 0149-2918 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092711A2 (fr) * 2005-03-02 2006-09-08 Ranbaxy Laboratories Limited Comprimes a liberation lente a base de metformine et de glipizide
WO2006092711A3 (fr) * 2005-03-02 2007-04-05 Ranbaxy Lab Ltd Comprimes a liberation lente a base de metformine et de glipizide
CN113616613A (zh) * 2021-08-30 2021-11-09 河南合智医药科技有限公司 一种治疗糖尿病用药二甲双胍格列吡嗪复方片剂及其制备方法

Also Published As

Publication number Publication date
WO2006077494A3 (fr) 2007-02-08

Similar Documents

Publication Publication Date Title
US20070172525A1 (en) Anti-diabetic combinations
US8911781B2 (en) Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
CA2592173C (fr) Formulation de complexe a liberation controlee destinee a une administration orale de medicament contre le diabete et procede de preparation correspondant
EP2486918A2 (fr) Composition pharmaceutique présentant à la fois des caractéristiques de libération lente et de libération immédiate
US20040202718A1 (en) Dosage form for treatment of diabetes mellitus
US20100330177A1 (en) Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
AU2011271124A1 (en) Controlled release compositions with reduced food effect
RU2435573C2 (ru) Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы
US20060141023A1 (en) Pharmaceutical compositions containing abiguanide-glitazone combination
AU2004283059B2 (en) Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20060002998A1 (en) Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
EP2996680A1 (fr) Compositions pharmaceutiques orales solides comprenant une combinaison de doses fixes de metformine et de sitagliptine ou de leurs sels
WO2005107717A2 (fr) Forme pharmaceutique orale pour la liberation prolongee d'un biguanide et d'une sulfonyluree
MXPA06001629A (es) Composicion nueva que comprende rosiglitazona y otro agente antidiabetico.
WO2006077494A2 (fr) Procede de preparation de formes dosifiees solides pour la liberation prolongee de biguanide et de sulfonyluree
JP2021526506A (ja) 糖尿病の治療において使用するためのトリアジン誘導体を含むフィルムコーティング錠剤
WO2006092711A2 (fr) Comprimes a liberation lente a base de metformine et de glipizide
US11684596B2 (en) Antidiabetic pharmaceutical compositions and preparation method thereof
EP3033075A1 (fr) Compositions pharmaceutiques orales solides comprenant une combinaison à dose fixe de metformine et de sitagliptine ou de sels de celles-ci
WO2006030303A1 (fr) Forme dosifiee administree par voie orale a liberation prolongee renfermant une dose elevee de biguanide et une faible dose de sulfonyluree
CN101940578B (zh) 一种用于治疗2型糖尿病的药物组合物及其制备方法
WO2005102290A1 (fr) Compositions pharmaceutiques formees d'un biguanide et d'une sulfonyluree
US20230277465A1 (en) Antidiabetic pharmaceutical compositions
WO2023007511A1 (fr) Composition pharmaceutique comprenant une combinaison d'un inhibiteur de sglt2 et d'un inhibiteur de dpp-iv
WO2005102273A2 (fr) Compositions pharmaceutiques a base d'un biguanide et d'une sulfonyluree

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 5902/DELNP/2007

Country of ref document: IN

122 Ep: pct application non-entry in european phase

Ref document number: 06710250

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6710250

Country of ref document: EP